SG11202006436SA - Methods for treating colorectal and metastatic colorectal cancers - Google Patents

Methods for treating colorectal and metastatic colorectal cancers

Info

Publication number
SG11202006436SA
SG11202006436SA SG11202006436SA SG11202006436SA SG11202006436SA SG 11202006436S A SG11202006436S A SG 11202006436SA SG 11202006436S A SG11202006436S A SG 11202006436SA SG 11202006436S A SG11202006436S A SG 11202006436SA SG 11202006436S A SG11202006436S A SG 11202006436SA
Authority
SG
Singapore
Prior art keywords
colorectal
methods
treating
cancers
metastatic
Prior art date
Application number
SG11202006436SA
Inventor
Karin Ganlöv
Magnus Östberg
Per Lindberg
Gunnel Sundén
Bengt Gustavsson
Original Assignee
Isofol Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/050274 external-priority patent/WO2019037899A1/en
Application filed by Isofol Medical Ab filed Critical Isofol Medical Ab
Publication of SG11202006436SA publication Critical patent/SG11202006436SA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202006436SA 2018-01-05 2019-01-04 Methods for treating colorectal and metastatic colorectal cancers SG11202006436SA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/EP2018/050274 WO2019037899A1 (en) 2017-08-24 2018-01-05 [6r]-mthf multiple bolus administration in 5-fluorouracil based chemotherapy
US201862651910P 2018-04-03 2018-04-03
US201862769289P 2018-11-19 2018-11-19
PCT/IB2019/000008 WO2019135157A1 (en) 2018-01-05 2019-01-04 Methods for treating colorectal and metastatic colorectal cancers

Publications (1)

Publication Number Publication Date
SG11202006436SA true SG11202006436SA (en) 2020-08-28

Family

ID=67143641

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006436SA SG11202006436SA (en) 2018-01-05 2019-01-04 Methods for treating colorectal and metastatic colorectal cancers

Country Status (15)

Country Link
EP (1) EP3735267B8 (en)
JP (1) JP7258759B2 (en)
KR (1) KR20200107988A (en)
CN (1) CN110573178A (en)
AU (1) AU2019205861A1 (en)
CA (1) CA3087514A1 (en)
DK (1) DK3735267T3 (en)
ES (1) ES2933266T3 (en)
HU (1) HUE061217T2 (en)
IL (1) IL275805A (en)
MX (1) MX2020007009A (en)
SG (1) SG11202006436SA (en)
SI (1) SI3735267T1 (en)
TW (1) TW201929901A (en)
WO (1) WO2019135157A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110538316B (en) * 2019-10-17 2021-10-15 滨州医学院 Use of 5-FU and glucagon in combination for the preparation of a medicament for the treatment of colorectal cancer and pharmaceutical compositions
WO2021185234A1 (en) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 Combined pharmaceutical composition of compound as c-met kinase inhibitor and use thereof
WO2023046307A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
WO2023046304A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
WO2023046305A1 (en) * 2021-09-27 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer
US20230095428A1 (en) * 2021-09-28 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of braf- or kras-mutated colorectal cancer
US20230097085A1 (en) * 2021-09-28 2023-03-30 Isofol Medical Ab [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer
CN114522227B (en) * 2022-01-24 2023-02-07 中山大学附属第六医院 Pharmaceutical composition for treating locally advanced microsatellite stable colorectal cancer and application

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097086A2 (en) * 2004-04-02 2005-10-20 Adventrx Pharmaceuticals, Inc. Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
CA2631755A1 (en) 2005-12-02 2007-06-07 Adventrx Pharmaceuticals, Inc. Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate
EP2837631A1 (en) 2013-08-14 2015-02-18 Merck & Cie New stable salt of 5,10-methylene-(6R)-tetrahydrofolic acid

Also Published As

Publication number Publication date
EP3735267A1 (en) 2020-11-11
TW201929901A (en) 2019-08-01
EP3735267B1 (en) 2022-09-14
SI3735267T1 (en) 2023-04-28
EP3735267B8 (en) 2022-11-09
RU2020122373A (en) 2022-02-07
DK3735267T3 (en) 2022-12-12
HUE061217T2 (en) 2023-05-28
ES2933266T3 (en) 2023-02-03
AU2019205861A1 (en) 2020-08-06
MX2020007009A (en) 2020-11-11
JP2021510140A (en) 2021-04-15
CN110573178A (en) 2019-12-13
WO2019135157A1 (en) 2019-07-11
JP7258759B2 (en) 2023-04-17
CA3087514A1 (en) 2019-07-11
KR20200107988A (en) 2020-09-16
IL275805A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
IL275805A (en) Methods for treating colorectal and metastatic colorectal cancers
IL272470A (en) Methods and materials for assessing and treating cancer
ZA202006627B (en) Methods and compositions for treating cancer
IL263224A (en) Methods and compositions for treating cancers
HK1256793A1 (en) Compounds and methods useful for treating or preventing hematological cancers
EP3134115A4 (en) Methods and compositions for treating metastatic breast cancer and other cancers in the brain
HK1251493A1 (en) Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
HK1257250A1 (en) Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
HK1250638A1 (en) Methods for treating egfr mutant cancers
IL274837A (en) Methods and compositions for treating cancers
IL276748A (en) Methods for prostate cancer detection and treatment
IL282478A (en) Materials and methods for treating cancer
IL288086A (en) Methods and materials for treating cancer
EP3796933A4 (en) Methods for treating, preventing and detecting the prognosis of colorectal cancer
SG11202012435UA (en) Compositions and methods for treating cancer
IL261146A (en) Methods and compositions for treating cancers and neoplasms
IL280395A (en) Tetrahydroquinolino derivatives for the treatment of metastatic and chemoresistant cancers
IL281167A (en) Kits and methods for treating cancers
EP3468564A4 (en) Methods for diagnosing and treating metastatic cancer
EP4055153A4 (en) Treatment for primary and metastatic cancer
GB201721569D0 (en) Method for the detection and treatment of colorectal adenomas
IL282313A (en) Abituzumab for the treatment of colorectal cancer
IL282948A (en) Compositions and methods for treating cancer
SG11202010208YA (en) The kit for screening colorectal cancer and advanced adenoma and its application
IL274714A (en) Methods and materials for assessing and treating cancer